Targeted missile drug aims to wipe out last traces of leukemia
NCT ID NCT03441061
Summary
This study is testing a targeted drug called inotuzumab ozogamicin for adults with B-cell acute lymphoblastic leukemia (ALL) who are in remission but still have tiny amounts of cancer cells detectable by sensitive tests. The drug is designed to seek out and destroy these remaining leukemia cells specifically. The main goal is to see if this treatment can prevent the cancer from coming back and improve how long patients live without relapse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.